- Home
- HBANL vs TGTX Comparison
HBANL vs TGTX Comparison
Compare HBANL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBANL
- TGTX
- Stock Information
- Founded
- HBANL N/A
- TGTX 1993
- Country
- HBANL United States
- TGTX United States
- Employees
- HBANL 20242
- TGTX N/A
- Industry
- HBANL Major Banks
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- HBANL Finance
- TGTX Health Care
- Exchange
- HBANL Nasdaq
- TGTX Nasdaq
- Market Cap
- HBANL N/A
- TGTX 4.2B
- IPO Year
- HBANL N/A
- TGTX 1995
- Fundamental
- Price
- HBANL $26.08
- TGTX $31.62
- Analyst Decision
- HBANL
- TGTX Strong Buy
- Analyst Count
- HBANL 0
- TGTX 4
- Target Price
- HBANL N/A
- TGTX $42.50
- AVG Volume (30 Days)
- HBANL N/A
- TGTX 2.1M
- Earning Date
- HBANL N/A
- TGTX 11-03-2025
- Dividend Yield
- HBANL N/A
- TGTX N/A
- EPS Growth
- HBANL N/A
- TGTX N/A
- EPS
- HBANL N/A
- TGTX 0.36
- Revenue
- HBANL N/A
- TGTX $454,069,000.00
- Revenue This Year
- HBANL N/A
- TGTX $82.58
- Revenue Next Year
- HBANL N/A
- TGTX $44.99
- P/E Ratio
- HBANL N/A
- TGTX $89.15
- Revenue Growth
- HBANL N/A
- TGTX 30.96
- 52 Week Low
- HBANL N/A
- TGTX $21.16
- 52 Week High
- HBANL N/A
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- HBANL 62.39
- TGTX 53.74
- Support Level
- HBANL $25.80
- TGTX $31.34
- Resistance Level
- HBANL $26.21
- TGTX $32.56
- Average True Range (ATR)
- HBANL 0.27
- TGTX 1.09
- MACD
- HBANL 0.04
- TGTX 0.44
- Stochastic Oscillator
- HBANL 86.63
- TGTX 65.83
About HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.